Quick Answer
ENANTA PHARMACEUTICALS INC reported Revenue From Contract With Customer Excluding Assessed Tax of $65.32 million for the year ending 2025.
- ENANTA PHARMACEUTICALS INC showed a decrease of -3.4% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from ENANTA PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on November 19, 2025.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), ENANTA PHARMACEUTICALS INC's Revenue From Contract With Customer Excluding Assessed Tax has declined by 26.0%.
- Historical annual values: Fiscal year 2025: $65.32 million | Fiscal year 2024: $67.64 million | Fiscal year 2023: $79.20 million | Fiscal year 2022: $86.16 million | Fiscal year 2021: $97.07 million | Fiscal year 2020: $122.47 million | Fiscal year 2019: $205.20 million | Fiscal year 2018: $206.63 million | Fiscal year 2017: $102.81 million | Fiscal year 2016: $88.27 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: